Literature DB >> 10425216

Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma.

K Asano1, S Okamoto, K Fukunaga, T Shiomi, T Mori, M Iwata, Y Ikeda, K Yamaguchi.   

Abstract

Platelet activating factor (PAF) is immediately degraded and inactivated in the bloodstream by plasma PAF acetylhydrolase (PAF-AH). Although plasma PAF-AH-like activity was secreted in vitro from various cell types such as macrophages and hepatocytes, the exact cellular source(s) of this enzyme activity in vivo remains unclear. There is a naturally-occurring missense mutation (V279F) in the plasma PAF-AH gene in the Japanese population which results in complete loss of the enzyme activity. We analyzed 52 Japanese who had received an allogeneic bone marrow transplant and maintained donor-derived hematopoiesis. Ten recipients had chimeric plasma PAF-AH genotypes between the donor-derived peripheral blood leukocytes and the recipient-derived epithelial cells of buccal mucosa. Multiple regression analysis demonstrated that PAF-AH activity in plasma depended on the donor's genotype (standardized regression coefficient = 0.68, P < 0.0001), but not on the recipient's genotype (p = 0.48). One recipient who was a V279F homozygote in leukocytes and wild type homozygote in buccal mucosa had undetectable PAF-AH activity in plasma. We conclude that most of the PAF-AH activity in human plasma originates from hematopoietic lineage cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425216     DOI: 10.1006/bbrc.1999.1066

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

2.  Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.

Authors:  Alexandros D Tselepis; George Hahalis; Constantinos C Tellis; Eleni C Papavasiliou; Panagiota T Mylona; Alexandra Kourakli; Dimitrios C Alexopoulos
Journal:  J Lipid Res       Date:  2010-07-12       Impact factor: 5.922

Review 3.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

Review 4.  Novel metabolic biomarkers of cardiovascular disease.

Authors:  Majken K Jensen; Monica L Bertoia; Leah E Cahill; Isha Agarwal; Eric B Rimm; Kenneth J Mukamal
Journal:  Nat Rev Endocrinol       Date:  2014-09-02       Impact factor: 43.330

5.  Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study.

Authors:  Annette L Fitzpatrick; Michael C Irizarry; Mary Cushman; Nancy S Jenny; Gloria C Chi; Carol Koro
Journal:  Atherosclerosis       Date:  2014-05-22       Impact factor: 5.162

6.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

7.  Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.

Authors:  Nels Olson; Ellen S O'Meara; Nancy S Jenny; Aaron R Folsom; Edwin G Bovill; Curt D Furberg; Susan R Heckbert; Bruce M Psaty; Mary Cushman
Journal:  Am J Hematol       Date:  2008-07       Impact factor: 10.047

8.  Differential expression of platelet-activating factor acetylhydrolase in lung macrophages.

Authors:  Katherine M Howard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-10-16       Impact factor: 5.464

9.  Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.

Authors:  Berna Atik; S Claiborne Johnston; Deborah Dean
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

10.  Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques.

Authors:  Dallit Mannheim; Joerg Herrmann; Daniele Versari; Mario Gössl; Fredric B Meyer; Joseph P McConnell; Lilach O Lerman; Amir Lerman
Journal:  Stroke       Date:  2008-03-20       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.